Cargando…

Patients’ Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western

Detalles Bibliográficos
Autores principales:	Seo, Hyungil, Ye, Byong Duk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849682/ https://www.ncbi.nlm.nih.gov/pubmed/27114431 http://dx.doi.org/10.5009/gnl16109

Ejemplares similares

Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
por: Ye, Byong Duk
Publicado: (2014)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea
por: Choi, Su Jin, et al.
Publicado: (2021)

Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Predicting the future of anti-tumor necrosis factor therapy
por: Verweij, Cornelis L
Publicado: (2009)

Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
por: Kim, Eun Soo, et al.
Publicado: (2016)

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
por: Lee, Jae Yong, et al.
Publicado: (2021)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
por: Shin, Ju-Young, et al.
Publicado: (2021)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn’s disease: a retrospective observational study
por: Park, Min Young, et al.
Publicado: (2021)

Are there interregional differences in the epidemiology and clinical characteristics of Crohn's disease in the Asia-Pacific region?
por: Lee, Sinwon, et al.
Publicado: (2016)

The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia
por: Hong, Seung Wook, et al.
Publicado: (2020)

Anti-tumor necrosis factor agents and COVID-19: A word of caution
por: Hajjar, Roy, et al.
Publicado: (2020)

The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease
por: Shim, Jung Ok, et al.
Publicado: (2018)

Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
por: Chun, Jaeyoung
Publicado: (2021)

Tumor necrosis factor: is it time to change the name?
por: Pisetsky, David S
Publicado: (2014)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
por: Papamichael, Konstantinos, et al.
Publicado: (2017)

Risk for multidrug-resistant tuberculosis in patients treated with anti-tumor necrosis factor agents
por: Park, Jinkyeong, et al.
Publicado: (2023)

Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature
por: Kothari, Mansi M, et al.
Publicado: (2017)

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2022)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population
por: Bounthavong, Mark, et al.
Publicado: (2014)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
por: Oh, Gyu Man, et al.
Publicado: (2020)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

Disaccharide Esters Screened for Inhibition of Tumor Necrosis Factor‐α Release Are New Anti‐cancer Agents
por: Okabe, Sachiko, et al.
Publicado: (1999)

The use of anti-interleukin-1 agents and tumor necrosis factor‐alpha inhibitors in renal transplant recipients
por: Yazısız, Veli, et al.
Publicado: (2021)

Tuberculosis infection versus anti-tumor necrosis factor therapy: screening challenges in psoriatic patients
por: Solovan, Caius, et al.
Publicado: (2012)

Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
por: Chu, Cong-Qiu
Publicado: (2021)

Systemic use of tumor necrosis factor alpha as an anticancer agent
por: Roberts, Nicholas J., et al.
Publicado: (2011)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent
por: Koo, Bon San, et al.
Publicado: (2015)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
por: Bouhuys, Marleen, et al.
Publicado: (2022)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Golimumab: A Novel Anti-Tumor Necrosis Factor
por: Rossini, Maurizio, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k473badkppuh1o0jba6gq5d7pl